Neuromodulation Devices Market Projected to Grow at 7.0% CAGR by 2033, Supported by Expanding Healthcare Infrastructure and Aging Population | DataM Intelligence

Leander, Texas and TOKYO, Japan - The Global Neuromodulation Devices Market was valued at US$ 98.05 billion in 2023, rose to US$ 104.26 billion in 2024, and is anticipated to climb to US$ 190.14 billion by 2033, registering a 7.0% CAGR from 2025 to 2033.

Market expansion is fueled by a growing burden of neurological conditions, rapid adoption of minimally invasive treatment options, continuous innovations in stimulation technologies, and broader use of neuromodulation in pain, psychiatric, and movement disorder therapies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/neuromodulation-devices-market?ram

United States: Key Industry Developments

✅ October 2025: US-based Ampa secured $8.5 million in funding to launch its FDA-cleared neuromodulation device, Ampa One, targeting major depressive disorder. The portable TMS system provides a single-day therapy protocol aimed at improving accessibility and efficiency in mental health care.

✅ July 2025: University of Minnesota spinout Neurotype received FDA clearance for its AI-powered wearable device designed to treat essential tremor, using artificial intelligence to personalize stimulation based on tremor patterns.

✅ July 2025: NeuroSigma unveiled a novel sensing technology for closed-loop spinal cord stimulation (SCS) systems, enabling real-time monitoring and adaptive stimulation for enhanced chronic pain management.

✅ June 2025: Boston Scientific received FDA approval for W4 and D4 lead splitters for the Precision PlusTM spinal cord stimulation system, improving multi-site lead placement flexibility to target pain areas more effectively.

✅ January 2025: Medtronic introduced a new deep brain stimulation (DBS) platform with adaptive stimulation technology that automatically adjusts based on real-time brain signals for conditions such as Parkinson's disease.

Asia Pacific / Japan: Key Industry Developments

✅ October 2025: Australis Scientific (Australia) won the MedTech Innovator Asia Pacific Grand Prize for its AI-driven smart neuromodulation patch targeting overactive bladder, offering a personalized, non-invasive nerve stimulation alternative.

✅ August 2025: China approved its first remote electrical neuromodulation (REN) wearable device for migraine treatment, providing a non-drug method for over 130 million patients.

✅ 2025: Japan's neurology devices market is experiencing growth driven by an aging population and rising neurological disorders like stroke, Alzheimer's, and Parkinson's. The market focuses on minimally invasive neurostimulation devices, integrating AI and machine learning for improved personalized treatments.

Mergers and Acquisitions (2025):

✅ Globus Medical - acquired Nevro Corp. for approximately $250 million in an all-cash transaction in April 2025. This deal strengthens Globus Medical's offerings in spinal cord stimulation devices for chronic pain management and taps into a large neuromodulation market opportunity.

✅ Boston Scientific - announced a definitive agreement to acquire Nalu Medical for approximately $533 million upfront in 2025. Nalu Medical develops miniaturized, battery-free neurostimulation systems targeting chronic pain, bolstering Boston Scientific's neuromodulation portfolio.

✅ electroCore - completed the acquisition of NeuroMetrix for $9 million in 2025, expanding its portfolio in non-invasive bioelectronic therapies for chronic pain and wellness.

✅ Firefly Neuroscience - acquired Evoke Neuroscience in 2025 to expand its EEG-based brain health tools with FDA-cleared hardware and software for cognitive function assessment.

✅ Aspen Medical Products - acquired Advanced Orthopaedics in 2025 to extend expertise beyond spinal innovation and tap into the bracing and supports market adjacent to neuromodulation.io.

Growth Drivers:

-Increasing prevalence of neurological and chronic pain disorders such as Parkinson's, epilepsy, Alzheimer's, and chronic pain due to aging populations, which demand effective long-term treatments.

-Technological advancements including device miniaturization, improved battery life, targeted stimulation techniques, and closed-loop systems that enhance patient outcomes and comfort.

-Expansion of neuromodulation therapies into a broader range of clinical applications like pain management, urinary and fecal incontinence, and epilepsy.

-Growing adoption of minimally invasive procedures and outpatient surgeries that reduce recovery times and hospital stays.

-Increasing reimbursement coverage and insurance support that broaden patient access and drive market adoption.

-Strong investments in neurotechnology research, regulatory approvals, and growing patient and healthcare provider awareness underpinning market growth globally, with North America currently leading and Asia-Pacific showing fastest growth potential.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=neuromodulation-devices-market?ram (Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis:

-By Product Type

Spinal Cord Stimulators: Largest segment due to widespread use in chronic pain management.

Deep Brain Stimulators: Key for treatment of neurological disorders like Parkinson's disease and tremors.

Sacral Nerve Stimulators: Used mainly for urinary and fecal incontinence.

Vagus Nerve Stimulators: Growing for epilepsy, depression, and migraine treatment.

Gastric Electrical Stimulation: Emerging for gastrointestinal disorders.

Others: Includes peripheral nerve stimulators and experimental devices.

-By Application

Parkinson's Disease: Major neurological disorder segment requiring stimulation therapies.

Chronic Pain: Leading application driving market growth due to need for non-opioid management options.

Epilepsy: Significant neurological disorder treated by vagus nerve and deep brain stimulation.

Migraine: Increasing use of neuromodulation for refractory cases.

Urinary & Fecal Incontinence: Driven by aging population and lifestyle factors.

Tremor, Depression, Others: Expanding indications, including psychiatric and movement disorders.

-By End User

Hospitals: Largest and fastest-growing end-user segment deploying advanced neuromodulation therapies.

Ambulatory Surgery Centers (ASC): Growing due to less invasive procedures and outpatient care trend.

Clinics & Physiotherapy Centers: Utilize devices for follow-up and non-invasive therapies.

Others: Includes rehabilitation centers and specialized neurology clinics.

Regional Insights:

North America: North America dominates the neuromodulation devices market with an estimated market share of about 37.8% in 2025. The region's market value is projected near USD 6.8 billion to 7 billion range. This dominance is driven by advanced healthcare infrastructure, high healthcare expenditure, a large patient population with neurological disorders, major industry players based here, strong regulatory frameworks, and robust reimbursement policies. The United States leads regional growth fueled by innovation in device technology and high diagnosis and treatment rates for neurological diseases.

Asia-Pacific: Asia-Pacific is expected to register the fastest growth during the forecast period, driven by rising neurological disorder prevalence, expanding healthcare infrastructure, increasing health awareness, and government support. The region's market share is rapidly increasing from a smaller base with emerging economies like China, India, and Japan as key contributors. The market growth is supported by expanding insurance coverage, growing disposable incomes, and the entry of local device manufacturers creating competitive markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neuromodulation-devices-market?ram

Key Players:

Medtronic | Abbott | Boston Scientific Corporation | Integer Holdings Corporation | ElectroCore | NeuroPace, Inc. | Nevro Corp | BrainsWay | Neuronetics | Soterix Medical Inc.

Key Highlights (Top 5 Key Players) for Neuromodulation Devices Market:

-Medtronic reported approximately USD 9.85 billion in fiscal year 2025 revenue from its Neuroscience Portfolio, which includes neuromodulation, with a low-double digit growth in the neuromodulation segment.

-Abbott holds the largest market share in the neuromodulation devices market at 16.7%, significantly contributing to the industry's revenue.

-Boston Scientific Corporation is a major player maintaining its strong market position through strategic partnerships and product innovation.

-Nevro Corp is also among the key contributors, actively engaged in the neuromodulation market with a notable presence.

-NeuroPace, Inc. stands as one of the recognized leaders in the market, contributing to the expanding neuromodulation devices industry revenue.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.